CompoAtlas

REVILAB PEPTIDE SL 09 (2023.)

Food supplement registered in Latvia

Register snapshot dated 2 May 2025. It does not establish the current status of the product.

Number published by PVD
0001403/2023
Type
Food supplement
Published status
Status not provided in this export; the validity date is shown separately
Licence holder
NPCRIZ Europe SIA
Manufacturer
SIA "HBO "VITA""
Origin
Latvija
Register snapshot
2 May 2025
Recommended daily intake (Latvian text)
5-10 pilieni 2 reizes dienā
Published pack size
10 ml
Published packaging
10 ml

This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

The foreign register category does not determine the regulatory category of the product in France.

Published composition

Published namePublished text and quantityRecognised ingredientRole or context
Ārstniecības kumelīteplants ; Ārstniecības kumelīte ; Chamomille recutita ; ekstrakts ; 24 ; mgNot recognisedRole not identified
Apelsīnsplants ; Apelsīns ; Citrus sinensis ; ēteriskā eļļa ; 2,4 ; mgcitrus sinensisPlant
Lakricaplants ; Lakrica ; Glycyrrhiza glabra ; ekstrakts ; 2,4 ; mgglycyrrhiza glabraPlant
Piparmētraplants ; Piparmētra ; Mentha piperita ; ekstrakts ; 2,4 ; mgmentha piperitaPlant
Krustnagliņa plants ; Krustnagliņa ; Syzygium aromaticum ; ēteriskā eļļa ; 0,12 ; mgsyzygium aromaticumPlant
Propolisa sausais ekstrakts otherNutrients ; Propolisa sausais ekstrakts ; 2,4 ; mgNot recognisedRole not identified
Dihidrokvercetīns (no Daurijas lapegles (Larix gmelinii) koksnes)otherNutrients ; Dihidrokvercetīns (no Daurijas lapegles (Larix gmelinii) koksnes) ; 1,2 ; mgNot recognisedRole not identified
Peptīdu komplekss AA-13, kas satur aminoskābes (L-glutamīnskābi un L-asparagīnskābi)otherNutrients ; Peptīdu komplekss AA-13, kas satur aminoskābes (L-glutamīnskābi un L-asparagīnskābi) ; 0,6 ; mgNot recognisedRole not identified
Peptīdu komplekss AA-12, kas satur aminoskābes (L-lizīnu, L-glutamīnskābi, L-asparagīnskābi un L-glicīnu)otherNutrients ; Peptīdu komplekss AA-12, kas satur aminoskābes (L-lizīnu, L-glutamīnskābi, L-asparagīnskābi un L-glicīnu) ; 0,3 ; mgNot recognisedRole not identified
Peptīdu komplekss AA-16, kas satur aminoskābes (L-lizīnu, L-glutamīnskābi, L-asparagīnskābi un L-prolīnu)otherNutrients ; Peptīdu komplekss AA-16, kas satur aminoskābes (L-lizīnu, L-glutamīnskābi, L-asparagīnskābi un L-prolīnu) ; 0,3 ; mgNot recognisedRole not identified
ŪdensotherIngredients ; Ūdens ; - ; mgNot recognisedRole not identified
Dabisks mentola aromatizētājsotherIngredients ; Dabisks mentola aromatizētājs ; - ; mgNot recognisedRole not identified
Limonēns, aromatizētājsotherIngredients ; Limonēns, aromatizētājs ; - ; mgNot recognisedRole not identified
Eigenols, aromatizētājsotherIngredients ; Eigenols, aromatizētājs ; - ; mgNot recognisedRole not identified
328foodAdditives ; 328Not recognisedRole not identified
181foodAdditives ; 181Not recognisedRole not identified
72foodAdditives ; 72Not recognisedRole not identified
74foodAdditives ; 74Not recognisedRole not identified
318foodAdditives ; 318Not recognisedRole not identified
246foodAdditives ; 246Not recognisedRole not identified

Quantities are reproduced as published. The export does not specify their basis: the recommended daily intake cannot be used to calculate a daily dose. No daily dose is estimated. Latvian names are retained without translation.

Manufacturer countries

Krievija

French and European references for recognised ingredients

Unrecognised ingredients are not assessed. The absence of a signal does not establish product compliance.

Official source

View the official register

Official PVD export

Internet Archive copy dated 3 May 2025

PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.

CC0 1.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Lakrica
    Read the warning, when it applies and the studies cited

    DEGLYCYRRHIZINATED LICORICE Buccal

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 31 October 2025

    Deglycyrrhizinated Licorice Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 31 January 2025

    LICORICE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Gardner and McGuffin 2013).

    Sources cited by Health Canada (1)
    • Gardner Z, McGuffin M. editors. 2013. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press.

    Condition of application: Cough relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if cough worsens or persists (for) more than 1 week (EMA 2012).

    Sources cited by Health Canada (1)
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf

    Condition of application: Gastritis relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Condition of application: All products.

    Do not use if you are pregnant (EMA 2012).

    Sources cited by Health Canada (2)
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
    • Gardner Z, McGuffin M. éditeurs. 2013. American Herbal Products Association's Botanical Safety Handbook, 2e édition. Boca Raton (FL): CRC Press.

    Do not use if you have hypokalemia, high blood pressure, or a kidney, liver or cardiovascular disorder (EMA 2012; Brinker 2010; ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (4)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (UK): British Herbal Medicine Association; 1992.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Do not use if you are taking heart medications, corticosteroids, stimulant laxatives, or other health products that may contribute electrolyte imbalance (Brinker 2010; ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000).

    Sources cited by Health Canada (4)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.

    Health Canada monograph dated 29 November 2024

  • Piparmētra
    Read the warning, when it applies and the studies cited

    PEPPERMINT - MENTHA X PIPERITA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gallstones or anemia (Brinker 2010; Mills and Bone 2005; Blumenthal et al. 2000).

    Sources cited by Health Canada (3)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Condition of application: Essential oil.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have hiatus hernia or gastroesophageal reflux (Brinker 2010; Mills and Bone 2005; ESCOP 2003).

    Sources cited by Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Known adverse reactions

    Condition of application: Essential oil.

    When using this product you may experience gastroesophageal reflux (Brinker 2010; Mills and Bone 2005; ESCOP 2003).

    Sources cited by Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Stop use if hypersensitivity/allergy occurs (Mills and Bone 2005; ESCOP 2003).

    Sources cited by Health Canada (2)
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Health Canada monograph dated 27 February 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “REVILAB PEPTIDE SL 09 (2023.)”, https://compoatlas.com/en/supplements/latvia/13907-revilab-peptide-sl-09-2023, updated 28 October 2026.

Enter to analyse, Shift+Enter for a new line